Preclinical and phase 1 studies of zilovertamab in CLL demonstrated tolerability and anti-tumor activity with inhibition of ROR1-signaling, cancer-stemness gene expression, and expression of genes induced by activation of extracellular signal-regulated kinase 1/2 (ERK1/2), nuclear factor-kappa B (NF-κB), and nuclear factor erythroid 2-related factor 2 (NRF2) [13]. This evidence concerns the gene NFKB1 and cancer.